Skip to main content
Top
Published in: Diabetologia 5/2012

01-05-2012 | Systematic Review

Treatment of acute Charcot foot with bisphosphonates: a systematic review of the literature

Authors: J.-L. Richard, M. Almasri, S. Schuldiner

Published in: Diabetologia | Issue 5/2012

Login to get access

Abstract

Aim/hypothesis

We undertook a systematic review of the literature concerning the efficacy and safety of bisphosphonates in acute Charcot neuropathic osteoarthropathy.

Methods

MEDLINE, PubMed, the Cochrane Database of Systematic Reviews, and abstracts presented during the meetings of the American Diabetes Association and the European Association of Diabetes were searched for relevant publications from the period January 1990 to September 2011.

Results

A total of ten studies on the treatment of acute Charcot osteoarthropathy with bisphosphonates were identified and included in the analysis. Only four clinical trials were published, three of which were randomised. Bisphosphonates appeared to induce significant reductions in skin temperature and bone turnover markers compared with placebo, without serious adverse events. Nevertheless, bisphosphonates did not shorten the immobilisation time. Moreover, no data were available regarding their long-term effects.

Conclusions/interpretations

Bisphosphonates have been shown to be effective for reducing bone turnover markers and skin temperature in some studies. Nevertheless, the long-term efficacy, specifically that regarding the occurrence of deformities and ulcerations, remains to be demonstrated as no follow-up studies have been published. Moreover, some studies have suggested that bisphosphonates may lengthen the resolution phase of the disease. In our opinion, the data are too weak to support the use of bisphosphonates as a routine treatment for acute Charcot neuroarthropathy.
Literature
1.
go back to reference Stanley JC, Collier AM (2008) Charcot osteo-arthropathy. Curr Orthop 22:428–433CrossRef Stanley JC, Collier AM (2008) Charcot osteo-arthropathy. Curr Orthop 22:428–433CrossRef
2.
go back to reference Sanders LJ, Frykberg RG (2007) The Charcot foot (Pied de Charcot). In: Bowker JH, Pfeifer MA (eds) Levin and O’Neal’s the diabetic foot. Mosby Elsevier, Philadelphia, pp 257–283 Sanders LJ, Frykberg RG (2007) The Charcot foot (Pied de Charcot). In: Bowker JH, Pfeifer MA (eds) Levin and O’Neal’s the diabetic foot. Mosby Elsevier, Philadelphia, pp 257–283
3.
go back to reference Wukich DK, Sung W (2009) Charcot arthropathy of the foot and ankle: modern concepts and management review. J Diabetes Complications 23:409–426PubMedCrossRef Wukich DK, Sung W (2009) Charcot arthropathy of the foot and ankle: modern concepts and management review. J Diabetes Complications 23:409–426PubMedCrossRef
4.
go back to reference van Baal J, Hubbard R, Game F, Jeffcoate W (2010) Mortality associated with acute Charcot foot and neuropathic foot ulceration. Diabetes Care 33:1086–1089PubMedCrossRef van Baal J, Hubbard R, Game F, Jeffcoate W (2010) Mortality associated with acute Charcot foot and neuropathic foot ulceration. Diabetes Care 33:1086–1089PubMedCrossRef
5.
go back to reference Rajbhandari RC, Jenkins CD, Tesfaye S (2002) Charcot neuroarthropathy in diabetes mellitus. Diabetologia 45:1085–1096PubMedCrossRef Rajbhandari RC, Jenkins CD, Tesfaye S (2002) Charcot neuroarthropathy in diabetes mellitus. Diabetologia 45:1085–1096PubMedCrossRef
6.
go back to reference Rogers LC, Frykberg RG, Armstrong DG et al (2011) The Charcot foot in diabetes. Diabetes Care 34:2123–2129PubMedCrossRef Rogers LC, Frykberg RG, Armstrong DG et al (2011) The Charcot foot in diabetes. Diabetes Care 34:2123–2129PubMedCrossRef
7.
go back to reference Jeffcoate WJ, Game F, Cavanagh PR (2005) The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 366:2058–2061PubMedCrossRef Jeffcoate WJ, Game F, Cavanagh PR (2005) The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 366:2058–2061PubMedCrossRef
8.
go back to reference Jeffcoate WJ (2008) Charcot neuro-osteoarthropathy. Diabetes Metab Res Rev 24:62–65CrossRef Jeffcoate WJ (2008) Charcot neuro-osteoarthropathy. Diabetes Metab Res Rev 24:62–65CrossRef
9.
go back to reference Molines L, Darmon P, Raccah D (2010) Charcot’s foot: newest findings on its pathophysiology, diagnosis and treatment. Diabetes Metab 36:251–255PubMedCrossRef Molines L, Darmon P, Raccah D (2010) Charcot’s foot: newest findings on its pathophysiology, diagnosis and treatment. Diabetes Metab 36:251–255PubMedCrossRef
10.
go back to reference Gough A, Abraha H, Li F et al (1997) Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic Charcot neuroarthropathy. Diabet Med 7:527–531CrossRef Gough A, Abraha H, Li F et al (1997) Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic Charcot neuroarthropathy. Diabet Med 7:527–531CrossRef
11.
go back to reference Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A (2008) Increased osteoclastic activity in acute Charcot’s osteoarthropathy: the role of receptor activator of nuclear factor-κB ligand. Diabetologia 51:1035–1040PubMedCrossRef Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A (2008) Increased osteoclastic activity in acute Charcot’s osteoarthropathy: the role of receptor activator of nuclear factor-κB ligand. Diabetologia 51:1035–1040PubMedCrossRef
12.
go back to reference Selby PL, Young MJ, Boulton AJ (1994) Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabet Med 11:28–31PubMedCrossRef Selby PL, Young MJ, Boulton AJ (1994) Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabet Med 11:28–31PubMedCrossRef
13.
go back to reference Lyn TA, Greenstein A, Jarrett S, McGonagle D (2005) Acute neuropathic joint disease. A medical emergency? Diabetes Care 28:2962–2964CrossRef Lyn TA, Greenstein A, Jarrett S, McGonagle D (2005) Acute neuropathic joint disease. A medical emergency? Diabetes Care 28:2962–2964CrossRef
14.
go back to reference Stansberry KB, Moss QE, Peppard HR, McNitt PM, Vinik AI (1999) Intravenous bisphosphonate rapidly reverses the paradoxical increase in blood flow to the foot in Charcot neuroarthropathy. Diabetes 48:A92 Stansberry KB, Moss QE, Peppard HR, McNitt PM, Vinik AI (1999) Intravenous bisphosphonate rapidly reverses the paradoxical increase in blood flow to the foot in Charcot neuroarthropathy. Diabetes 48:A92
15.
go back to reference Guis S, Pellissier JF, Arniaud D et al (1999) Healing of Charcot’s joint by pamidronate infusion. J Rheumatol 26:1843–1845PubMed Guis S, Pellissier JF, Arniaud D et al (1999) Healing of Charcot’s joint by pamidronate infusion. J Rheumatol 26:1843–1845PubMed
16.
go back to reference Young MT (1999) The management of neurogenic arthropathy: a tale of two Charcots. Diabetes Metab Res Rev 15:59–64PubMedCrossRef Young MT (1999) The management of neurogenic arthropathy: a tale of two Charcots. Diabetes Metab Res Rev 15:59–64PubMedCrossRef
17.
go back to reference Pakarinen T-K, Laine H-J, Honkonnen SE, Peltonen J, Oksala H, Lahtela J (2002) Charcot arthropathy of diabetic foot: current concepts and review of 36 cases. Scand J Surg 9:195–201 Pakarinen T-K, Laine H-J, Honkonnen SE, Peltonen J, Oksala H, Lahtela J (2002) Charcot arthropathy of diabetic foot: current concepts and review of 36 cases. Scand J Surg 9:195–201
18.
go back to reference Moreno M, Gratacós J, Casado E, Galisteo C, Orellana C, Larrosa M (2007) Utilidad del pamidronato en el tratamiento de la artropatía de Charcot (Usefulness of pamidronate in the treatment of Charcot’s arthropathy). Reumatol Clin 3:257–261, article in SpanishPubMedCrossRef Moreno M, Gratacós J, Casado E, Galisteo C, Orellana C, Larrosa M (2007) Utilidad del pamidronato en el tratamiento de la artropatía de Charcot (Usefulness of pamidronate in the treatment of Charcot’s arthropathy). Reumatol Clin 3:257–261, article in SpanishPubMedCrossRef
19.
go back to reference Naqvi A, Cuchacovich R, Saketkoo L, Espinoza LR (2008) Acute Charcot arthropathy successfully treated with Pamidronate: long-term follow-up. Am J Med Sci 335:145–148PubMedCrossRef Naqvi A, Cuchacovich R, Saketkoo L, Espinoza LR (2008) Acute Charcot arthropathy successfully treated with Pamidronate: long-term follow-up. Am J Med Sci 335:145–148PubMedCrossRef
20.
go back to reference Anderson JJ, Woelffer KE, Holtzman JJ, Jacobs AM (2004) Bisphophonates for the treatment of Charcot neuroarthropathy. J Foot Ankle Surg 43:2285–2289 Anderson JJ, Woelffer KE, Holtzman JJ, Jacobs AM (2004) Bisphophonates for the treatment of Charcot neuroarthropathy. J Foot Ankle Surg 43:2285–2289
21.
go back to reference Jude EB, Selby PL, Burgess J, Lilleystone P, Mawer EB et al (2001) Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 44:2032–2037PubMedCrossRef Jude EB, Selby PL, Burgess J, Lilleystone P, Mawer EB et al (2001) Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 44:2032–2037PubMedCrossRef
22.
go back to reference Pitocco D, Ruotolo V, Caputo S et al (2005) Six-month treatment with Alendronate in acute Charcot neuroarthropathy. Diabetes Care 28:1214–1215PubMedCrossRef Pitocco D, Ruotolo V, Caputo S et al (2005) Six-month treatment with Alendronate in acute Charcot neuroarthropathy. Diabetes Care 28:1214–1215PubMedCrossRef
23.
go back to reference Pakarinen T-K, Laine H-J, Mäenpää H, Mattila P, Lahtela J (2011) The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy. A pilot randomized controlled trial. Diabetes Care 34:1514–1516PubMedCrossRef Pakarinen T-K, Laine H-J, Mäenpää H, Mattila P, Lahtela J (2011) The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy. A pilot randomized controlled trial. Diabetes Care 34:1514–1516PubMedCrossRef
24.
go back to reference Vega D, Maalouf NM, Sakhaee K (2007) The role of receptor activator of nuclear factor-κB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92:4514–4521PubMedCrossRef Vega D, Maalouf NM, Sakhaee K (2007) The role of receptor activator of nuclear factor-κB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92:4514–4521PubMedCrossRef
25.
go back to reference Uccioli L, Sinistro A, Almerighi C et al (2010) Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot. Diabetes Care 33:350–355PubMedCrossRef Uccioli L, Sinistro A, Almerighi C et al (2010) Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot. Diabetes Care 33:350–355PubMedCrossRef
26.
go back to reference Pitocco D, Zelano G, Gioffré G et al (2009) Association between osteoprotegerin G1181C and T245G polymorphisms and diabetic Charcot neuroarthropathy. A case–control study. Diabetes Care 32:1694–1697PubMedCrossRef Pitocco D, Zelano G, Gioffré G et al (2009) Association between osteoprotegerin G1181C and T245G polymorphisms and diabetic Charcot neuroarthropathy. A case–control study. Diabetes Care 32:1694–1697PubMedCrossRef
28.
go back to reference Pinzur MS, Lio T, Posner M (2006) Treatment of Eichenholtz stage 1 Charcot foot arthropathy with a weightbearing total contact cast. Foot Ankle Int 27:324–329PubMed Pinzur MS, Lio T, Posner M (2006) Treatment of Eichenholtz stage 1 Charcot foot arthropathy with a weightbearing total contact cast. Foot Ankle Int 27:324–329PubMed
29.
go back to reference Frith JC, Mönkkönen J, Auriola S, Mönkkönen H, Rogers MJ (2001) The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44:2201–2210PubMedCrossRef Frith JC, Mönkkönen J, Auriola S, Mönkkönen H, Rogers MJ (2001) The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44:2201–2210PubMedCrossRef
30.
go back to reference Russell RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759PubMedCrossRef Russell RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759PubMedCrossRef
31.
go back to reference Maksymowych WP (2002) Bisphosphonates—anti-inflammatory properties. Curr Med Chem Anti Inflamm Anti Allergy Agents 1:15–28CrossRef Maksymowych WP (2002) Bisphosphonates—anti-inflammatory properties. Curr Med Chem Anti Inflamm Anti Allergy Agents 1:15–28CrossRef
32.
go back to reference Smith C, Kumar S, Causby R (2007) The effectiveness of non-surgical interventions in the treatment of Charcot foot. Int J Evid Based Healthc 5:437–449PubMedCrossRef Smith C, Kumar S, Causby R (2007) The effectiveness of non-surgical interventions in the treatment of Charcot foot. Int J Evid Based Healthc 5:437–449PubMedCrossRef
33.
go back to reference Game FL, Catlow R, Jones GR, Edmonds ME, Jude EB, Rayman G, Jeffcoate WJ (2012) Audit of acute Charcot’s disease in the UK: the CDUK study. Diabetologia 55:32–35PubMedCrossRef Game FL, Catlow R, Jones GR, Edmonds ME, Jude EB, Rayman G, Jeffcoate WJ (2012) Audit of acute Charcot’s disease in the UK: the CDUK study. Diabetologia 55:32–35PubMedCrossRef
34.
go back to reference Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045PubMedCrossRef Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045PubMedCrossRef
35.
go back to reference Bem R, Jirkovská A, Fejfarová V, Skibová J, Jude EB (2006) Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy. A randomized clinical trial. Diabetes Care 29:1392–1394PubMedCrossRef Bem R, Jirkovská A, Fejfarová V, Skibová J, Jude EB (2006) Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy. A randomized clinical trial. Diabetes Care 29:1392–1394PubMedCrossRef
Metadata
Title
Treatment of acute Charcot foot with bisphosphonates: a systematic review of the literature
Authors
J.-L. Richard
M. Almasri
S. Schuldiner
Publication date
01-05-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2507-3

Other articles of this Issue 5/2012

Diabetologia 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.